Many people naturally assume that the claims made for foods and nutritional supplements have the same degree of scientific grounding as those for medication, but that is not always the case. The IOM recommends that the FDA adopt a consistent scientific framework for biomarker evaluation in order to achieve a rigorous and transparent process.
and Medicine National Academies of Sciences, Engineering, Institute of Medicine, Board on Health Sciences Policy, Forum on Neuroscience and Nervous System Disorders, Clare Stroud, Sheena Posey Norris, Lisa Bain
National Academy of Engineering, National Academy of Sciences, Policy and Global Affairs, Institute of Medicine, and Public Policy Committee on Science, Engineering, Panel on Scientific Communication and National Security
Institute of Medicine, Division of Health Promotion and Disease Prevention, Division of Health Sciences Policy, Committee for Evaluating Medical Technologies in Clinical Use
Institute of Medicine, Food and Nutrition Board, Board on Health Sciences Policy, Board on Health Care Services, Committee on Qualification of Biomarkers and Surrogate Endpoints in Chronic Disease, Christine M. Micheel, Erin Balogh, Alison Mack
and Medicine National Academies of Sciences, Engineering, Institute of Medicine, Board on Health Care Services, Committee on Diagnostic Error in Health Care, John R. Ball, Bryan T. Miller, Erin P. Balogh
Institute of Medicine, Board on Health Sciences Policy, Committee on Creating a Vision for Space Medicine During Travel Beyond Earth Orbit, Jr. Evans, Charles H., John R. Ball
Institute of Medicine, Board on Health Sciences Policy, Board on Health Care Services, Committee on the Review of Omics-Based Tests for Predicting Patient Outcomes in Clinical Trials, Gilbert S. Omenn, Sharly J. Nass, Christine M. Micheel